Navigation Links
R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Date:9/10/2007

ctions. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is expected to enter Phase 3 clinical trials for registration in the Americas and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a Phase 1 clinical trial through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

About R7128

R7128 is being developed for the treatment of chronic hepatitis C. R7128 is a prodrug of PSI-6130, which demonstrated potency in preclinical studies. PSI-6130 is a pyrimidine nucleoside analog inhibitor of HCV RNA polymerase, an enzyme that is necessary for hepatitis C viral replication. Results from an oral single ascending dose study of PSI-6130 in 24 healthy male volunteers showed that PSI-6130 was generally well tolerated with no serious adverse events in doses up to 3000 mg.

R7128 Phase 1 Study Overview

The Phase 1 clinical trial is a multiple center, observer-blinded, randomized and placebo-controlled study to investigate the pharmacokinetics, pharmacodynamics, safety, tolerability and food effect of R7128 in healthy volunteers and in patients chronically infected with HCV genotype 1. This Phase 1 study is comprised of two parts:

- Part 1 is a single ascending dose study of R7128 conducted in 46

healthy volunteers. The primary objective of Part 1 is to assess the

safety, tolerability and pharmacokinetics of R7128 following single

ascending doses under fasting conditions. The secondary objective of

P
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
9. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
10. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015 Although lung ... the world, there are only 18 drugs in the ... Almita and Avastin are nearing their patent expiry in ... therapeutics market offers vast potential that drug manufacturers are ... treatment of small cell lung cancer (SCLC) and non-small ...
(Date:3/3/2015)... , March 3, 2015 ImmunoCellular Therapeutics, ... Andrew Gengos , Chief Executive Officer of ImmunoCellular, will ... 27 th Annual ROTH Conference on Tuesday, March ... Hotel, Laguna Niguel , CA.   ... the ROTH presentation, please log on through a link ...
(Date:3/3/2015)... , March 3, 2015 Chrono Therapeutics ... an investment by Rock Health , the leading ... of Chrono,s SmartStop™ programmable transdermal drug delivery system and ... Smoking kills more than 500,000 Americans each year, ... in the United States . Of ...
Breaking Medicine Technology:Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments 2Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments 3ImmunoCellular Therapeutics to Present at ROTH Conference on March 10th 2Chrono Therapeutics Receives Investment from Rock Health to Advance SmartStopTM Smoking Cessation Technology 2Chrono Therapeutics Receives Investment from Rock Health to Advance SmartStopTM Smoking Cessation Technology 3
... N.J., Sept. 28 Laureate Pharma, Inc., ... company, today announced the appointment of Steven ... Mr. Johnson will be responsible for Laureate,s ... business development and project management, supporting the ...
... JUNCTION, N.J., Sept. 28 Tamir Biotechnology, Inc. ... Corporation) announced today that scientists supported by the ... reported test results confirming two of our lead ... cell culture and plaque reduction assay (the gold ...
Cached Medicine Technology:Laureate Pharma Appoints Steven R. Johnson as Vice President, Business Development 2New Discovery Targets Cytomegalovirus (CMV) 2New Discovery Targets Cytomegalovirus (CMV) 3New Discovery Targets Cytomegalovirus (CMV) 4
(Date:3/3/2015)... Prophecy Healthcare®, Inc., the nation's ... testing, is now conducting dedicated research to expand ... of acquiring the exam rights and Intellectual Property ... the research will soon create more health care ... healthcare staffing organizations and more. , ...
(Date:3/3/2015)... 2015 Extend Nutrition, a leading nutritional snack ... of calories consumed at the next meal by an average ... are no lifestyle changes needed and no program to abide ... , The starter kit contains 60 servings of nutritional bars, ... protein, fiber, healthy fat and complex carbohydrates that helps to ...
(Date:3/3/2015)... 03, 2015 Getting to the truth of ... and well-being are at stake. So when it comes to ... move about pain-free – it’s vital to separate fact from ... resource, according to Sridhar Yalamanchili, PT, MSPT, and Director of ... A September 2014 nationwide survey by the American Physical Therapy ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Human ... that it’s offering a new master health insurance plan ... its clients with a group platform removing potential cost ... Master Health Plan has been in effect since January ... clients with much need medical cost savings. , The ...
(Date:3/3/2015)... Sponsors of Medicare Advantage (MA) plans and stand-alone ... changes to sift through as a result of CMS’s ... Feb. 20. The potential pay changes alone are tough ... type and location of the plan’s membership. But there ... before CMS issues the final notice and when 2016 ...
Breaking Medicine News(10 mins):Health News:Prophecy Healthcare Acquires IP to Expand Behavioral Benchmarks 2Health News:Prophecy Healthcare Acquires IP to Expand Behavioral Benchmarks 3Health News:Snack Your Way to a Smaller Waistline with Extend Nutrition’s New “Snack-2-Health Kit” 2Health News:Snack Your Way to a Smaller Waistline with Extend Nutrition’s New “Snack-2-Health Kit” 3Health News:Separating Fact from Fiction about Physical Therapy 2Health News:Separating Fact from Fiction about Physical Therapy 3Health News:HCBR Group Offers Master Healthcare Plan through Humana 2Health News:March 12 Webinar to Analyze Implications of CMS’s ’45-Day Notice’ and 2016 Call Letter for MA and Part D Plans 2
... PORTLAND, Ore. Researchers at Oregon Health & Science University,s ... women at high-risk for ovarian cancer who also want to ... which serve as the "breeding ground" for ovarian cancer, may ... would be a vast improvement over the current prevention strategy ...
... HealthDay Reporter , WEDNESDAY, April 6 (HealthDay News) ... not to mention the Grim Reaper, a new study from ... go shopping daily live longer than their less shopping-prone peers. ... women, according to the study, which was published recently in ...
... TORONTO, Ont., April 7, 2011 Virtual reality and other ... according to research from St. Michael,s Hospital. Patients ... up to five times more likely to show improvements in ... "Virtual reality gaming is a promising and potentially ...
... doctors more accountable for health care quality, more attention must ... to evaluate caregivers, says a prominent Johns Hopkins patient safety ... Health Affairs , Peter J. Pronovost, M.D., Ph.D., a ... Hopkins University School of Medicine, argues that as the desire ...
... Biology and Medicine is pleased to announce the 2011 ... $500 travel grant for undergraduate/ graduate students and/or individuals ... members of the Society to attend the Experimental Biology ... of their research work which were evaluated by a ...
... three-year follow-up study of patients in the Hepatitis ... revealed that increased mortality among patients with advanced ... was attributed to non-liver related causes and occurred ... to this excess mortality was evident to researchers, ...
Cached Medicine News:Health News:Ovarian cancer finding may be a 'win-win' for at-risk women who wish to have a family 2Health News:'Retail Therapy' Might Really Work 2Health News:'Retail Therapy' Might Really Work 3Health News:Video games effective treatment for stroke patients: study 2Health News:Unreliable 'outcomes' measures hamper efforts to assure better, safer care 2Health News:Unreliable 'outcomes' measures hamper efforts to assure better, safer care 3Health News:SEBM Young Investigator Awards for 2011 2Health News:Increased mortality rates seen in chronic hepatitis C patients with pre-cirrhotic advanced fibrosis 2Health News:Increased mortality rates seen in chronic hepatitis C patients with pre-cirrhotic advanced fibrosis 3
... Our most popular onsite test! QuickScreen multi-panel ... urine sample, and your choice of any ... multi-panels offer total flexibility for your drug ... the specimen and the built-in timer tells ...
... The SureStep™ Drug Screen Tests are available ... for MDMA (Ecstasy). Designed using Microgenics Antibody ... the only point of care immunoassay targeted ... for both MDA and MDEA but no ...
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
... drugs of abuse tests are highly accurate in ... recommended cut-off as confirmed by GC/MS testing. This ... specific alternative method (such as GC/MS) must be ... Professional judgment should be applied to any drug ...
Medicine Products: